SciClone Pharmaceuticals, Inc. provided earnings guidance for the year 2012. For the period, the company anticipates 2013 sales revenue of $150 million - $155 million. Non-GAAP EPS of $0.66 - $0.72 per share.

The company anticipates 2013 year-end cash and investments balances to be greater than $105 million excluding any impacts on cash balance associated with the company's acquisition of new products, ongoing stock repurchase program and any other unbudgeted one-time cash expenses.